Explore › Outcome › Stillbirth
Outcome

Stillbirth

Also known as: SB - Stillbirth Stillbirth Stillbirth (disorder) Stillbirth (finding) Stillbirth (finding) [Ambiguous] Stillbirth, NOS Stillbirths
3 findings 1 paper 4 related entities View in graph →

Related entities

interventions
non-dolutegravir antiretroviral drug exposure1
conditions
HIV1
populations
Pregnant Women1
studys
PMC106140301

Findings (27)

None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →
None
decline

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Size: aRR 2.10 CI: 95% CI 1.24-3.55
PMC10614030
Finding details → · Paper → · Graph →

Papers (1)